tgfb

Events

Partner Content

Are you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development?

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.